Marketing
How "Gilead Blew the Lights Out" with Sovaldi
A report by ISI’s Mark Schoenenbaum shows that Gilead’s Sovaldi literally “blew out the lights” in U.S. “specialty drug” sales during its first full year on the market. This remarkable prescription drug will come in somewhere between $10 and $11 billion dollars in sales for 2014. Tom Norton wonders how the Sovaldi’s first year might size up against the broader chronic category drugs...Read more
Technology
Health 2.0: Health Apps Steal the Show
Two of the industry's most influential conferences— TEDMED (Washington, DC) and Health 2.0 (San Francisco, CA) — occurred within weeks of each other this autumn. Pharm Exec Editorial Advisory Board member Bill Drummy was at both events and found the upcoming trends easy to see...Read more
Leadership
Pharma’s Middle Management Challenge
The challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity ...Read more
Special Feature
Pharm Exec’s 2015 Pipeline Report
This year's pipeline report checks in on the emerging technologies, as well as potential therapies to address metabolic and neurodegenerative diseases. There's a lot to like in the pipeline and more than a little competitive drama to make it really interesting. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers? ...Read more
| 
